These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 1312587

  • 1. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial.
    Burkes RL, Ginsberg RJ, Shepherd FA, Blackstein ME, Goldberg ME, Waters PF, Patterson GA, Todd T, Pearson FG, Cooper JD.
    J Clin Oncol; 1992 Apr; 10(4):580-6. PubMed ID: 1312587
    [Abstract] [Full Text] [Related]

  • 2. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial.
    Burkes RL, Shepherd FA, Blackstein ME, Goldberg ME, Waters PF, Patterson GA, Todd T, Pearson FG, Jones D, Farooq S, McGlaughlin J, Ginsberg RJ.
    Lung Cancer; 2005 Jan; 47(1):103-9. PubMed ID: 15603860
    [Abstract] [Full Text] [Related]

  • 3. [A pilot study of induction chemotherapy with cisplatin, mitomycin C and vindesine for stage III N2 non-small cell lung cancer].
    Nishiwaki Y, Nagai K, Kodama T, Nishiyama H, Hojo H, Matsumoto T.
    Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31 Suppl():203-11. PubMed ID: 8007467
    [Abstract] [Full Text] [Related]

  • 4. Induction chemotherapy for stage IIIA unresectable non-small cell lung cancer: the Toronto experience and an overview.
    Goldberg M, Burkes RL.
    Semin Surg Oncol; 1993 Dec; 9(2):108-13. PubMed ID: 8387687
    [Abstract] [Full Text] [Related]

  • 5. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P, Herndon J, Langer M, Kohman LJ, Elias AD, Kass FC, Eaton WL, Seagren SL, Green MR, Sugarbaker DJ.
    Cancer; 1996 Jun 01; 77(11):2393-9. PubMed ID: 8635112
    [Abstract] [Full Text] [Related]

  • 6. Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective study. Leuven Lung Cancer Group.
    Vansteenkiste JF, De Leyn PR, Deneffe GJ, Lievens YN, Nackaerts KL, Van Raemdonck DE, van der Schueren E, Lerut TE, Demedts MG.
    Ann Oncol; 1998 Mar 01; 9(3):261-7. PubMed ID: 9602259
    [Abstract] [Full Text] [Related]

  • 7. Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer.
    Li J, Dai CH, Yu LC, Chen P, Li XQ, Shi SB, Wu JR.
    Clin Lung Cancer; 2009 Sep 01; 10(5):353-9. PubMed ID: 19808194
    [Abstract] [Full Text] [Related]

  • 8. Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung. LCSG 881.
    Wagner H, Lad T, Piantadosi S, Ruckdeschel JC.
    Chest; 1994 Dec 01; 106(6 Suppl):348S-354S. PubMed ID: 7988262
    [Abstract] [Full Text] [Related]

  • 9. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F, Sica G, De Filippis S, Rosselli M, Saggio G, Guerriero G, Pompili P, Rea S.
    Anticancer Res; 2000 Dec 01; 20(3B):1985-90. PubMed ID: 10928138
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group.
    Furuse K, Kubota K, Kawahara M, Kodama N, Ogawara M, Akira M, Nakajima S, Takada M, Kusunoki Y, Negoro S.
    J Clin Oncol; 1995 Apr 01; 13(4):869-75. PubMed ID: 7707113
    [Abstract] [Full Text] [Related]

  • 11. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
    Scagliotti GV, Fossati R, Torri V, Crinò L, Giaccone G, Silvano G, Martelli M, Clerici M, Cognetti F, Tonato M, Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators.
    J Natl Cancer Inst; 2003 Oct 01; 95(19):1453-61. PubMed ID: 14519751
    [Abstract] [Full Text] [Related]

  • 12. Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques).
    Riggi M, Ruffie P, Voisin S, Monnet I, de Cremoux H, Saltiel JC, Martin M, Vergne L, Huet J, Cvitkovic E.
    Eur J Cancer; 1991 Oct 01; 27(10):1238-42. PubMed ID: 1659842
    [Abstract] [Full Text] [Related]

  • 13. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials.
    Pisters KM, Kris MG, Gralla RJ, Zaman MB, Heelan RT, Martini N.
    J Clin Oncol; 1993 Sep 01; 11(9):1757-62. PubMed ID: 8394881
    [Abstract] [Full Text] [Related]

  • 14. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209).
    Nagai K, Tsuchiya R, Mori T, Tada H, Ichinose Y, Koike T, Kato H, Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group.
    J Thorac Cardiovasc Surg; 2003 Feb 01; 125(2):254-60. PubMed ID: 12579093
    [Abstract] [Full Text] [Related]

  • 15. Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease).
    Phernambucq EC, Biesma B, Smit EF, Paul MA, vd Tol A, Schramel FM, Bolhuis RJ, Postmus PE.
    Br J Cancer; 2006 Aug 21; 95(4):470-4. PubMed ID: 16909132
    [Abstract] [Full Text] [Related]

  • 16. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
    Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR.
    J Clin Oncol; 1995 Aug 21; 13(8):1880-92. PubMed ID: 7636530
    [Abstract] [Full Text] [Related]

  • 17. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.
    Fukuoka M, Masuda N, Furuse K, Negoro S, Takada M, Matsui K, Takifuji N, Kudoh S, Kawahara M, Ogawara M.
    J Clin Oncol; 1991 Apr 21; 9(4):606-13. PubMed ID: 1648597
    [Abstract] [Full Text] [Related]

  • 18. Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma.
    Ng KK, Kris MG, Ginsberg RJ, Heelan RT, Pisters KM, Miller VA, Grant SC, Bains M, Rusch V, Rosenzweig KE, Martini N.
    Cancer; 1999 Oct 01; 86(7):1189-97. PubMed ID: 10506703
    [Abstract] [Full Text] [Related]

  • 19. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients.
    Martini N, Kris MG, Flehinger BJ, Gralla RJ, Bains MS, Burt ME, Heelan R, McCormack PM, Pisters KM, Rigas JR.
    Ann Thorac Surg; 1993 Jun 01; 55(6):1365-73; discussion 1373-4. PubMed ID: 8390230
    [Abstract] [Full Text] [Related]

  • 20. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).
    Gridelli C, Perrone F, Palmeri S, D'Aprile M, Cognetti F, Rossi A, Gebbia V, Pepe R, Veltri E, Airoma G, Russo A, Incoronato P, Scinto AF, Palazzolo G, Natali M, Leonardi V, Gallo C, De Placido S, Bianco AR.
    Ann Oncol; 1996 Oct 01; 7(8):821-6. PubMed ID: 8922196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.